The pharmaceutical community is buzzing with anticipation surrounding retatrutide, a new dual GIP and GLP-1 target that’s demonstrating significant promise in clinical trials for managing obesity. Unlike some existing weight loss solutions, retatrutide appears to offer a significant substantial decrease in body weight and enhance metabolic marker